Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Checkpoint drugs' regulatory reckoning looms

<< Previous

Bullboard Posts

Next >>

Comment by JohnnyYegon Mar 15, 2021 6:11pm

261 Views

Post# 32804213

RE:RE:RE:Checkpoint drugs' regulatory reckoning looms

Oh, I think (nothing substantiative) there is PLENTY of interest with big pharma. I think ONCY is evaluating the best course of action for the company, to make best use of Pelareorep in the market place for cancer patients. The payout will be there, but I think there will be a more altruistic goal than just shareholder return. Remember, Matt Coffey started this journey after his mother was stricken with breast cancer.

<< Previous

Bullboard Posts

Next >>

A junior copper-gold stock trading at a bargain of monumental proportions